Sanofi, GSK begin phase 1/2 clinical trial of Covid-19 vaccine candidate

This article was originally published here

Both firms have worked together to develop a vaccine candidate, which applies the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines with GSK’s pandemic adjuvant

The post Sanofi, GSK begin phase 1/2 clinical trial of Covid-19 vaccine candidate appeared first on Pharmaceutical Business review.